Nitrofurantoin-induced fulminant hepatitis mimicking autoimmune hepatitis [2]

Annals of Pharmacotherapy

Volumn 40, Issue 10, 2006, Pages 1888-1889

  Peedikayil, Musthafa Chalikandy ^a   Dahhan, Talal Ibrahim ^a   Al Ashgar, Hamad Ibrahim ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

CILAZAPRIL; LEVOTHYROXINE; METHYLPREDNISOLONE; NITROFURANTOIN; PHENAZOPYRIDINE; SIMVASTATIN;

ACUTE HEPATITIS; AGED; AUTOIMMUNE HEPATITIS; CASE REPORT; CAUSE OF DEATH; CHOLESTASIS; CHRONIC HEPATITIS; DETERIORATION; DIFFERENTIAL DIAGNOSIS; DRUG WITHDRAWAL; FEMALE; HEPATITIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; JAUNDICE; LABORATORY TEST; LETTER; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FAILURE; LIVER INJURY; PRIORITY JOURNAL; URINARY TRACT INFECTION;

AGED; DIAGNOSIS, DIFFERENTIAL; FEMALE; HEPATITIS, AUTOIMMUNE; HUMANS; LIVER FAILURE, ACUTE; NITROFURANTOIN;

EID: 33749608819     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H136     Document Type: Letter

References (7)

1. Thiim M, Friedman LS. Hepatotoxicity of antibiotics and antifungals. Clin Liver Dis 2003;7:381-99, vi-vii.
2. Sharp JR, Ishak KG, Zimmerman HJ. Chronic active hepatitis and severe hepatic necrosis associated with nitrofurantoin. Ann Intern Med 1980;92:14-9.
3. Alvarez F, Berg PA, Blanchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929-38.
4. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
5. Badley BW. Phenazopyridine-induced hepatitis. Br Med J 1976;2:850.
6. Goldfinger SE, Marx S. Hypersensitivity hepatitis due to phenazopyridine hydrochloride. N Engl J Med 1972;286:1090-1.
7. Marzoa-Rivas R, Crespo-Leiro MG, Paniagua-Marin MJ, et al. Safety of statins when response is carefully monitored: a study of 336 heart recipients. Transplant Proc 2005;37:4071-3.